Dr. Tianqiang Song 宋天强
Chief Physician
Department of Hepatobiliary Oncology, Tianjin Medical University Cancer Institute & Hospital, Tianjin
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Surgical treatment of primary liver, bile duct, gallbladder, and pancreatic cancers, plus liver metastases from colorectal or breast cancer. Uses intraoperative ultrasound, laparoscopic and robotic surgery, 3D visualization, and radiofrequency ablation.
Dr. Song earned a master’s from Tianjin Medical University in 1997 and a PhD in oncology in 2003. Training included fellowships at Memorial Sloan Kettering (2005) and MD Anderson (2008), plus studies in Japan, Korea, Taiwan, and Hong Kong. Dr. Song leads the Hepatobiliary Tumor Department.
Professional roles
- Standing Committee Member, Oncology Branch, Chinese Medical Association
- Standing Committee Member, Surgical Oncology Committee, China Medical Doctor Association
- Standing Committee Member, Digestive Surgery Branch, Chinese Research Hospital Association
- Member, Liver Cancer Professional Committee, China Anti-Cancer Association
Name order: in Chinese the family name comes first (Song Tianqiang). Papers usually list the name as Tianqiang Song or Song T.
Selected publications
116 papers on PubMed matched by name and affiliation; 26 as first or senior author since 2016. Most recent first- or senior-author papers:
- Nutr Hosp, 2026 (senior author): Response to: "Multivariable modeling in clinical nutrition research: methodological considerations for stability and interpretability". PubMed 42299045
- MedComm (2020), 2026 (senior author): Perioperative Camrelizumab and Apatinib for High-Risk Resectable Hepatocellular Carcinoma: A Phase II Study. PubMed 42872135
- Drug Resist Updat, 2026 (senior author): Perioperative tislelizumab for early-stage hepatocellular carcinoma: A phase II trial with integrated tumour microenvironment profiling and predictive modeling. PubMed 42385524
- Nat Commun, 2026 (senior author): Perioperative tislelizumab plus lenvatinib treatment for resectable hepatocellular carcinoma at high risk of recurrence: single-arm phase II trial. PubMed 41501032
- Cancers (Basel), 2025 (senior author): Individualized Prediction of Postoperative Survival in Gallbladder Cancer: A Nomogram Based on SEER Data and External Validation. PubMed 40563569
- Nutr Hosp, 2025 (senior author): Influence of handgrip strength on postoperative complications and survival in primary liver cancer patients. PubMed 40066574
- World J Gastroenterol, 2024 (senior author): Lenvatinib, sintilimab combined interventional treatment vs bevacizumab, sintilimab combined interventional treatment for intermediate-advanced unresectable hepatocellular carcinoma. PubMed 39575400
- J Hepatocell Carcinoma, 2024 (senior author): Benefit of Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma: A Propensity Score-Matched Study. PubMed 39360035
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion